Please login to the form below

Not currently logged in
Email:
Password:

EC lays formal antitrust charges against Servier

French firm accused of blocking entry of generic Coversyl/Aceon

French pharma company Servier has been formally charged by the European Commission of blocking the entry of generic versions of its cardiovascular medicine Coversyl/Aceon (perindopril) in collusion with four generic drugmakers.

The "statement of objections" follows swiftly after similar charges were laid against Lundbeck and eight generics firms for delaying the launch of cut-price versions of its Cipramil (citalopram) antidepressant.

In this latest action, the EC is claiming that patent settlement agreements between Servier and Teva, Matrix (now Mylan), Niche/Unichem, Krka and Lupin were specifically designed to delay the entry of generics of perindopril "in violation of EU antitrust rules".

The Commission is also claiming that privately-held Servier acquired "scarce competing technologies" to block the production of generic perindopril.

"These practices could have aimed at preserving Servier's position with regard to perindopril, which was about to reach the end of its patent protection," said the EC in a statement.

Servier has been under the spotlight for the alleged pay-for-delay deals since 2009, when a formal investigation was first announced.

Meanwhile, in addition to Lundbeck, other active investigations are focusing on Johnson & Johnson's pain drug Duragesic (fentanyl) and Cephalon's narcolepsy treatment Provigil (modafinil). Both these cases also cite Teva. Another investigation involving AstraZeneca and Nycomed was dropped in March.

The anticompetition investigations were launched after unannounced inspections at pharmaceutical companies in November 2008.

If the Commission can prove wrongdoing on the behalf of the pharma companies they can be liable to a fine equivalent to up to 10 per cent of annual worldwide turnover.

Servier has said it has not yet received a copy of the complaint from the EC but was confident it had not breached EU antitrust rules.

A related investigation into the French pharma company, which suggested Servier has provided "misleading and incorrect information" in the perindopril probe, was dropped earlier this year after the Commission concluded it would be too time-consuming and burdensome to investigate the matter.

Financial regulators on both sides of the Atlantic have been scrutinising agreements between branded and generic drugmakers, with a federal appeals court in the US earlier this month siding with the Federal Trade Commission's position that the deals are anticompetitive.

31st July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics